'Unmet Needs And Thinking Big,' Inari Buys LimFlow For $250m To Add CLTI Treatment

LimFlow recently earned FDA approval for its transcatheter deep-vein arterialization system for the treatment of chronic limb-threatening ischemia. Inari, which has previously focused on venous thromboembolism, believes LimFlow's total addressable market could be worth over $4bn annually, with no direct competition in sight.

Vein becoming artery with LimFlow crossing stent
Vein becoming artery with LimFlow crossing stent • Source: LimFlow SA

Inari Medical plans to pay up to $415m for Paris-based LimFlow SA to add the LimFlow transcatheter deep-vein arterialization system to its portfolio of peripheral vascular interventional devices, the companies announced on 1 November.

“Our ethos and mission are focused on addressing significant unmet needs and thinking big,” Inari CEO Andrew Hykes said during Inari’s third-quarter 2023 earnings calls on 1 November. “LimFlow is...

LimFlow CEO Dan Rose said, “By joining with Inari and benefitting from their exceptional resources and capabilities, we expect to be well-positioned to increase access to our technology and advance...

More from Deals

More from Business